Skip to content
Nobel Jews
Portrait of Robert J. Lefkowitz
Photo: Bengt Nyman, Flickr: IMG_4781 · CC BY 2.0 via Wikimedia Commons

Nobel Prize in Chemistry · 2012

Robert J. Lefkowitz

He helped prove that the cell's hormone 'receivers' are real molecules and revealed the receptor family a third of all drugs act on.

The Nobel citation: “for studies of G-protein-coupled receptors”
Born
April 15, 1943, New York, NY, USA
Shared with
Brian Kobilka
Affiliation at the time
Howard Hughes Medical Institute, USA; Duke University Medical Center, USA

Chemistry prize

2012

Shared with 1 other laureate.

Age that year

69years

Born in 1943.

Headline credited impact

$44–52billion in economic value

Cumulative global sales of drugs that act on G-protein-coupled receptors, 1990-2025 (a proxy for economic activity). How it was built

Sources cited

25

Fact-checked September 24, 2026.

  • He went into research partly because of the Vietnam War: a Public Health Service post at the NIH let young doctors serve without being sent to war.
  • A few months into a run of failed experiments at the NIH, he and his father agreed he was not cut out to be a scientist. His father died of a heart attack weeks later.
  • A cardiologist who became a heart patient: after his father died at 63 of a heart attack, Lefkowitz himself needed quadruple bypass surgery in 1994.
  • He was the eighth Nobel laureate from the Bronx High School of Science. The seven before him had all won in physics.
  • As late as the 1970s, even the pharmacologist who had named the alpha and beta receptors doubted that they physically existed.

The breakthrough

Proving receptors are real and finding the G-protein-coupled receptor family

Every cell is wrapped in a thin, oily skin called the membrane. Hormones such as adrenaline cannot pass through it, yet within seconds they change what happens inside the cell. For decades scientists guessed that cells carry 'receptors' on their surface, like doorbells that ring inside the house when a visitor presses the button outside. Many doubted these were real objects at all. Lefkowitz set out to prove they were. He attached radioactive tags to hormones and drugs so he could detect and count the few receptors that grabbed them. In 1974 his Duke team used a radioactive beta blocker to tag the beta-adrenergic receptor, the one adrenaline uses to speed up the heart. His lab then spent about a decade pulling these rare receptors out of cell membranes, which required purifying them about 100,000-fold, and showed that the purified protein, slipped into cells that lacked it, made them respond to adrenaline-like drugs. In 1986, working with Brian Kobilka and a team from the drug company Merck, they read the receptor's gene. The protein snaked back and forth through the membrane seven times, just like rhodopsin, the light sensor in the eye. That surprise revealed a whole family, now called G-protein-coupled receptors, with about a thousand genes in humans for sight, smell, taste, hormones and brain chemicals. His lab also found how active receptors are switched off: enzymes called GRKs mark them, and proteins called beta-arrestins then block them.[2],[3],[4],[5]

“Jewish boy from the Bronx, loves to read. Dreams of being a doctor.”
Robert J. Lefkowitz, Asked by Duke Today in a 2017 interview to tell his life story in three sentences. His third sentence said the boy somehow became a scientist who won the Nobel Prize.[8]

What it meant for humanity

G-protein-coupled receptors help steer almost everything the body does, from heart rate and blood pressure to mood, sight, smell and taste. That makes them the largest family of drug targets. A 2017 count found 475 drugs, about 34% of all drugs approved in the United States, acting on 108 of these receptors; a 2025 update counted 516 drugs, 36% of the total. They include beta blockers for heart disease, antihistamines for allergies, many psychiatric medicines, and newer diabetes and obesity drugs. Lefkowitz did not invent most of these medicines. Beta blockers, for example, were in use before anyone had isolated a receptor. His contribution was to turn receptors from an abstract idea into molecules that could be measured, purified, cloned and studied. He writes that his binding methods changed how drug companies screened candidate drugs and how new receptor subtypes were found, and that the cloned receptor sequences let other labs find many new 'orphan' receptors, now studied as possible drug targets. His lab's discovery of how receptors are switched off, through GRK enzymes and beta-arrestins, helps explain why some drugs lose their effect over time. Mutations that leave a receptor switched on even without a hormone, which his lab stumbled on while studying adrenergic receptors, are now known to cause a growing list of diseases. The idea of 'biased' drugs, which trigger only some of a receptor's signals and which his lab helped develop, has become a major research direction, though its first medicines have had mixed results. He also trained more than 200 scientists, including his co-laureate Brian Kobilka.

  • A 2017 analysis found 475 approved drugs, about 34% of all drugs approved by the US Food and Drug Administration, acting on 108 G-protein-coupled receptors. A 2025 update counted 516 drugs, or 36%.[15],[16],[25]
  • Drugs aimed at these receptors made up about 27% of the global market for therapeutic drugs, with combined sales of about US$890 billion from 2011 to 2015.[15]
  • Cloning the beta2-adrenergic receptor in 1986 showed it resembled rhodopsin, the eye's light sensor, revealing a family now known to include about a thousand human genes.[3],[5]
  • Lefkowitz writes that his receptor-counting methods reshaped how drug candidates were tested, and that other labs used the cloned receptor genes to find many new 'orphan' receptors, now studied as possible drug targets.[2]
  • Receptor mutations that keep a receptor switched on without any hormone, which his lab found by chance, are now linked to a growing list of inherited and acquired diseases.[2],[5]
  • He trained more than 200 students and fellows, among them Brian Kobilka, who shared the 2012 prize with him.[2],[5]

Impact in numbers

Lefkowitz's main legacy is knowledge. He proved that receptors are real molecules, isolated them, and with Kobilka revealed the receptor family that about a third of all approved drugs act on. We count that through one outcome: cumulative world sales of drugs acting on these receptors, about $4.4 to $5.2 trillion from 1990 to 2025. Sales measure spending, not health gained. We credit him with only 1%, because most major drug classes aimed at these receptors, from antihistamines to beta blockers and opioids, were found by classical pharmacology before any receptor had been isolated, and because Kobilka, the discoverers of G proteins and generations of drug developers share the credit. We make no lives-saved claim, since no study separates his contribution from that of the drugs themselves. Much of his impact cannot be counted: proof that receptors exist, the concept of receptor switch-off through GRKs and beta-arrestins, tools that let hundreds of labs find new receptors, and more than 200 scientists he trained.

HealthFundamental scienceEconomy

Each number is the laureate’s credited share of a real-world outcome, cumulative to 2025. The whole outcome, the share of credit, and the reasoning are shown so you can check the arithmetic. Outcomes shared with other laureates are counted once on the impact page.

  • Low confidenceRippleModeledEconomy

    Cumulative global sales of drugs that act on G-protein-coupled receptors, 1990-2025 (a proxy for economic activity)

    $44–52

    billion in economic value, credited share

    That is 1% of $4.4–5.2 trillion in economic value since 1990.

    How this number was built

    Hauser 2017: GPCR drugs ~27% of the drug market; 2011-15 sales ~$890B (~$178B/yr). IMS prescription sales (WHO 2004, Table 4.2): $127.7B in 1990, $282.5B in 2000. Low: 27% gives $34.5B (1990) and $76.3B (2000); 1990-2000 = 11 yrs x $55.4B avg = $0.61T; 2001-10 = 10 x avg($76.3B, $178B) = $1.27T; 2011-15 = $0.89T; 2016-25 flat at $160B = $1.60T; total $4.37T. High: 35% share (Sriram & Insel: ~35% of approved drugs) gives $44.7B and $98.9B; 1990-2000 = $0.79T; 2001-10 = 10 x avg($98.9B, $178B) = $1.38T; 2011-15 = $0.89T; 2016-25 = $178B growing 3%/yr = $2.10T; total $5.16T. Nominal dollars, probably an undercount; sales measure spending, not benefit. Share 0.01: most GPCR drug classes predate receptor isolation; Kobilka, G-protein discoverers and drug developers share the rest.[2],[15],[16],[17],[18],[25]

    Sources: Nature Reviews Drug Discovery (via PubMed Central); PubMed (US National Library of Medicine); Nature Reviews Drug Discovery (PubMed abstract); Molecular Pharmacology (via PubMed Central); World Health Organization; NobelPrize.org

The double edge

No weapons or deliberate harms are tied to Lefkowitz's work. The main controversies concern whether his later ideas have delivered. In the late 2000s he co-founded the company Trevena to develop 'biased' drugs. Its heart-failure drug TRV027 did no better than a placebo in a 621-patient trial published in 2017. Its painkiller oliceridine was designed to favour one of the signals sent by the receptor that morphine acts on. In 2018 an FDA advisory panel voted 8 to 7 against approving it; some members said tests had not shown less breathing suppression than morphine, and some worried that people would wrongly see it as safer, which could encourage abuse. The FDA approved it in 2020 with boxed warnings about addiction and life-threatening breathing suppression, and Trevena stopped selling it at the end of 2024 for business reasons. A 2019 mouse study also found that sharply reducing beta-arrestin recruitment did not reduce opioid side effects, undercutting the idea behind such drugs. In a wider debate over whether the chemistry prize has become a biology prize, Lefkowitz called the question an unproductive argument about definitions.

  • Minor

    A 'biased' opioid did not prove safer

    Oliceridine, from Lefkowitz's company Trevena, was meant to relieve pain with fewer side effects. An FDA panel voted 8 to 7 against it in 2018, with some members noting that tests in healthy volunteers did not show less breathing suppression than morphine. It was approved in 2020 with boxed warnings about addiction and life-threatening breathing suppression, and Trevena stopped selling it at the end of 2024 for business reasons.[2],[19],[20],[21]

  • Minor

    The theory behind safer opioids was challenged

    Lefkowitz's Nobel lecture cited mouse studies suggesting that opioid side effects run through beta-arrestin2. A 2019 study of mice whose opioid receptors were increasingly unable to recruit beta-arrestins found breathing suppression, constipation and withdrawal unchanged or worse, predicting that such drugs would still cause severe side effects.[5],[22]

  • Minor

    A biased heart-failure drug failed its trial

    Trevena's TRV027, the beta-arrestin-biased angiotensin-receptor drug that Lefkowitz's Nobel lecture described (as TRV120027) slowing heart failure in animals, gave no benefit over placebo at any dose in a 621-patient trial of acute heart failure published in 2017.[5],[23]

  • Minor

    Chemistry prize or biology prize?

    Some researchers argue that the chemistry Nobel has drifted toward the life sciences, with at least nine such prizes since 2000. Asked about it, Lefkowitz, whose own prize was for receptor biology, called it an unproductive argument about definitions, while saying he understood why other chemists felt left out.[24]

Against the odds

Lefkowitz did not face persecution, and we found no record that antisemitism blocked his own path. His family's history explains why he grew up in New York at all. His father's parents left the Częstochowa area of Poland in 1903 or 1904; he has written that they were fleeing pogroms. According to a 2021 profile, family members who stayed behind died in the Holocaust. In 1942 about 40,000 Jews from Częstochowa were deported to the Treblinka death camp. In America, some of the doors he walked through had only recently opened. Columbia's medical school, where he earned his MD in 1966, had cut Jewish students from 47% of new admissions in 1920 to 6% in 1940, and a 1957 study still found Jewish applicants to medical schools accepted at lower rates. The medical historian Edward Halperin notes that such quotas were still widespread in US medical schools when the Second World War ended, and gone within about 25 years. Duke, where he built his career from 1973, had held Jewish undergraduates to 3% or less in the 1930s and asked applicants their religion until the early 1960s. Lefkowitz entered Columbia's medical school in 1962 at 19; the sources we found do not say that quotas affected him. One of his hardest years came at the NIH, when a run of failed experiments coincided with the sudden death of his father.

  • 1903

    Persecution

    His paternal grandparents emigrated from the Częstochowa area of Poland to New York in 1903 (his 2021 essay says 1904). Lefkowitz has written that they were fleeing the pogroms then sweeping Eastern Europe.[2],[6]

  • 1942

    Family killed

    Lefkowitz has written that branches of his family never made it out of Europe and that he believes relatives died in the Holocaust. In 1942 about 40,000 Jews from Częstochowa, his grandparents' home town, were deported to Treblinka.[6],[10],[14]

  • —

    Quota

    Jewish students fell from 47% of new admissions at Columbia's College of Physicians and Surgeons in 1920 to 6% in 1940. A 1957 study still found lower acceptance rates for Jewish medical school applicants, and quotas faded only by about 1970. Lefkowitz entered in 1962; we found no record that a quota affected him.[2],[11],[12]

  • —

    Discrimination

    Duke University, where he spent his career from 1973, had held Jewish undergraduate enrollment to 3% or less from 1930 to 1937 and asked applicants to state their religion until the early 1960s. This is context for his workplace, not something he is recorded as facing.[13]

Jewish background

Both parents JewishIdentified as Jewish, secular

Lefkowitz was born in the Bronx to Max and Rose Lefkowitz. In his Nobel autobiography he writes that he is Jewish and that all four grandparents were Eastern European Jewish immigrants: his father's parents came from the Częstochowa area of Poland, his mother's from Russia. His maternal grandmother's brother, Solomon Polachek, was a noted rabbi and Talmud scholar who taught at Yeshiva University's rabbinical seminary. As a boy he attended a monthly club of his paternal grandmother's Kremsdorf relatives. He calls himself a 'Jewish boy from the Bronx', has written about relatives he believes died in the Holocaust, and is a member of Beth El Synagogue in Durham.[2],[6],[7],[8],[9],[10]

Key dates

  1. April 15, 1943

    Born in New York City and raised in the Bronx, the only child of Max, an accountant, and Rose, an elementary school teacher.[1],[2]

  2. 1959

    Graduates from the Bronx High School of Science at 16 and enters Columbia College as a pre-medical chemistry student.[2],[7]

  3. 1962

    Finishes Columbia College in three years, at 19, and starts at Columbia's College of Physicians and Surgeons.[2]

  4. 1966

    Earns his MD from Columbia and begins two years of training in internal medicine at Columbia-Presbyterian Medical Center.[2],[3]

  5. July 1, 1968

    Joins the NIH as a Public Health Service officer, a path around the Vietnam-era doctor draft, and is assigned to hunt for hormone receptors.[2]

  6. 1970

    Publishes his first receptor papers, on the ACTH hormone receptor, then moves to Massachusetts General Hospital for residency and cardiology training.[2],[4]

  7. July 1, 1973

    Joins the Duke University faculty to build a program in 'molecular cardiology'. He stays at Duke for the rest of his career.[1],[2]

  8. 1974

    With postdoc Marc Caron, develops a radioactive beta-blocker probe that tags beta-adrenergic receptors directly.[2]

  9. 1986

    His lab, with Brian Kobilka and a Merck team, clones the beta2-adrenergic receptor gene and finds it resembles rhodopsin, revealing a receptor family.[4],[5]

  10. 1990

    His lab clones beta-arrestin, a protein that shuts down activated receptors.[5]

  11. 1994

    Has quadruple bypass heart surgery after developing angina at 50.[2]

  12. 2007

    Receives the US National Medal of Science and the Shaw Prize in Life Science and Medicine.[2]

  13. October 10, 2012

    Named co-winner of the Nobel Prize in Chemistry 'for studies of G-protein-coupled receptors', sharing it equally with his former fellow Brian Kobilka.[1],[3]

  14. 2021

    Publishes a memoir, 'A Funny Thing Happened on the Way to Stockholm', written with his former postdoc Randy Hall.[6],[10]

Sources

  1. 1.Robert J. Lefkowitz - Facts · NobelPrize.org (Nobel Prize Outreach)
  2. 2.Robert J. Lefkowitz - Biographical (from The Nobel Prizes 2012) · NobelPrize.org, 2013
  3. 3.Press release: The Nobel Prize in Chemistry 2012 · NobelPrize.org (Royal Swedish Academy of Sciences), 2012
  4. 4.The Nobel Prize in Chemistry 2012 - Popular information: Cells and sensibility · Royal Swedish Academy of Sciences (via NobelPrize.org), 2012
  5. 5.A Brief History of G Protein Coupled Receptors (Nobel Lecture, 8 December 2012) · NobelPrize.org, 2012
  6. 6.How winning a Nobel Prize helped me to find my roots (Robert Lefkowitz with Randy Hall), Wayback Machine copy · The Forward, 2021
  7. 7.New York Jews won't stop winning Nobel Prizes (Mark Schulte) · The Times of Israel, 2012
  8. 8.An Interview with Bob Lefkowitz, Five Years After His Nobel · Duke Today (Duke University), 2017
  9. 9.Speaker Night: Bob Lefkowitz and Ray Greenberg · Beth Meyer Synagogue, Raleigh, 2021
  10. 10.How a Nobel-winning 'accidental scientist' changed the world by saving himself (Rich Tenorio) · The Times of Israel, 2021
  11. 11.The Jewish Problem in U.S. Medical Education, 1920-1955 (Edward C. Halperin, Journal of the History of Medicine 56) · Journal of the History of Medicine and Allied Sciences (via Jewish Historical Society of South Carolina), 2001
  12. 12.Event: Why Did the United States Medical School Admissions Quota for Jews End? (Edward C. Halperin) · Rubenstein Library, Duke University Libraries, 2019
  13. 13.Obstacles to Learning - Down Home: Jewish Life in North Carolina · Duke University (Sites@Duke)
  14. 14.Monument to Treblinka deportees dedicated · Jewish Telegraphic Agency, 2009
  15. 15.Trends in GPCR drug discovery: new agents, targets and indications (Hauser AS et al., Nat Rev Drug Discov 16:829-842), author manuscript · Nature Reviews Drug Discovery (via PubMed Central), 2017
  16. 16.GPCR drug discovery: new agents, targets and indications (Lorente JS et al., Nat Rev Drug Discov 24:458-479) · Nature Reviews Drug Discovery (PubMed abstract), 2025
  17. 17.G protein-coupled receptors as targets for approved drugs: how many targets and how many drugs? (Sriram K, Insel PA, Mol Pharmacol 93:251-258) · Molecular Pharmacology (via PubMed Central), 2018
  18. 18.The World Medicines Situation (WHO/EDM/PAR/2004.5), Table 4.2 · World Health Organization, 2004
  19. 19.Final Summary Minutes of the Anesthetic and Analgesic Drug Products Advisory Committee Meeting, October 11, 2018 (oliceridine) · US Food and Drug Administration, 2018
  20. 20.Trevena Announces FDA Approval of OLINVYK (oliceridine) injection · Trevena, Inc., 2020
  21. 21.Trevena, Inc. Form 8-K (Item 8.01): discontinuation of OLINVYK (oliceridine) injection sales, filed January 15, 2025 · US Securities and Exchange Commission (EDGAR), 2025
  22. 22.Phosphorylation-deficient G-protein-biased mu-opioid receptors improve analgesia and diminish tolerance but worsen opioid side effects (Kliewer A et al., Nat Commun 10:367) · Nature Communications (PubMed abstract), 2019
  23. 23.Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: BLAST-AHF (Pang PS et al., Eur Heart J 38:2364-2373) · European Heart Journal (PubMed abstract), 2017
  24. 24.Has the chemistry Nobel prize really become the biology prize? (Philip Ball) · Chemistry World (Royal Society of Chemistry), 2020
  25. 25.Trends in GPCR drug discovery: new agents, targets and indications (Hauser AS et al., Nat Rev Drug Discov 16:829-842), published abstract · PubMed (US National Library of Medicine), 2017

Fact-checked on September 24, 2026 by a separate AI fact-checking pass that re-opened the sources, with 14 corrections made. How we check

Suggest a correction